02289 CHARMACY PHAR
- 13.940
- -0.040-0.29%
CHARMACY PHAR News
CHARMACY PHAR To Go Ex-Dividend On May 22nd, 2024 With 0.33082 HKD Dividend Per Share
April 27th - $CHARMACY PHAR(02289.HK)$ is trading ex-dividend on May 22nd, 2024. Shareholders of record on May 23rd, 2024 will receive 0.33082 HKD dividend per share on July 10th, 2024. The ex-div
創美藥業：2023年報
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump
Charmacy Pharmaceutical Co., Ltd. (HKG:2289) shareholders have had their patience rewarded with a 40% share price jump in the last month. The last 30 days bring the annual gain to a very sharp 90%.
Charmacy Pharmaceutical 2023 Profit Declines on Lower Asset Disposal Gains
Charmacy Pharmaceutical (HKG:2289) posted a 2023 net profit attributable to shareholders of 51.3 million yuan, or 0.4754 yuan per share, down from 90.5 million yuan, or 0.8377 yuan per share, a year e
Chuangmei Pharmaceutical (02289) will pay a final dividend of 0.3 yuan per share on July 10
Chuangmei Pharmaceutical (02289) announced that the company will pay a final dividend of 0 per share on July 10, 2024...
Chuangmei Pharmaceutical (02289) announced 2023 annual results, net profit of 51.34 million yuan, down 43.25% year on year
Chuangmei Pharmaceutical (02289) disclosed the 2023 annual results announcement. The group achieved operating income of 44.0 during the reporting period...
CHARMACY PHAR: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Committed efforts have yielded results | Chuangmei Pharmaceutical (2289.HK) has won many honors in pharmaceutical cold chain logistics
Recently, the “2024 (10th) Pharmaceutical Cold Chain Industry Chain International Summit”, supported by the Pharmaceutical Business Committee of the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce and organized by the Pharmaceutical Chain Circle Platform, was held in Taizhou, Jiangsu. With its outstanding performance in the field of pharmaceutical cold chain logistics, Chuangmei Pharmaceutical was awarded the “2023-2024 Pharmaceutical Cold Chain Logistics Service Recommended Enterprise” and “2023-2024 Pharmaceutical Cold Chain Best Logistics Center (Base)”. Lin Zhijie, vice president of Chuangmei Pharmaceutical Group, was honored as “2023-20234 Pharmaceutical Cold Chain Logistics Best Logistics Center (Base)”. According to reports, the purpose of the selection of awards is to recognize instruments
Charmacy Pharmaceutical's Profit to Drop by 45% in 2023
Charmacy Pharmaceutical (HKG:2289) expects a 45% year-over-year decline in attributable profit for the year 2023, the pharmaceutical products distributor said in a March 15 filing on the Hong Kong bou
Chuangmei Pharmaceutical (02289.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui, March 15, 丨 Chuangmei Pharmaceutical (02289.HK) announced that the board of directors meeting will be held on March 28, 2024 (Thursday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and consider recommending payment of a final dividend (if any).
Chuangmei Pharmaceutical (02289) Fa Ying Guang expects net profit to fall by about 45% year on year in 2023
Chuangmei Pharmaceutical (02289) issued an announcement. The Group expects the year ended December 31, 2023 (reporting period...
CHARMACY PHAR: NOTICE OF BOARD MEETING
CHARMACY PHAR: PROFIT WARNING
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
Guotai Junan: The pharmaceutical industry has a low market risk appetite and selects “cost-effective” stocks with steady management
Guotai Junan released a research report saying that the high base effect in COVID-related fields dissipated throughout the year, and the growth rate is expected to gradually return to its own path, but Q1, especially in January-February, was still affected by the base effect of the epidemic.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Analysis
Price Target
No Data
